Orin M. Goldblum

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Alan Menter, Kenneth B. Gordon, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2010 · 159 citations

Life Sciences, Dermatology, Immunology +9

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Eric L. Simpson, Seth Forman, Jonathan I. Silverberg et al. · Journal of the American Academy of Dermatology · 2021 · 135 citations

Life Sciences, Dermatology, Pharmacology +11

Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3

P.C.M. van de Kerkhof, Lyn Guenther, A.B. Gottlieb et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 82 citations

Medicine, Pharmacology, Pharmacotherapy +11

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis

Richard G. Langley, Phoebe Rich, Alan Menter et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 80 citations

Medicine, Dermatology, Pharmacotherapy +15

Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

Bruce Strober, Jeffrey M. Sobell, Kristina Callis Duffin et al. · British Journal of Dermatology · 2012 · 67 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17